Veracyte Names Kevin Haas as Chief Development and Technology Officer Veracyte (Nasdaq: VCYT) named Kevin Haas, Ph.D., as Chief Development and Technology Officer, effective March 24, 2026. The newly created role will oversee end-to-end product development across assays, software, bioinformatics, and the product development program office to support MRD and multi-omics initiatives.Dr. Haas brings more than 15 years of life sciences experience, including senior technology and bioinformatics leadership roles at Myriad and Counsyl, and holds a Ph.D. in chemical engineering from UC Berkeley.

#VCYT Veracyte Names Kevin Haas as Chief Development and Technology Officer

www.stocktitan.net/news/VCYT/veracyte-names...

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results Total revenue of between $138 million and $140 million, an increase of between 16% and 18% Testing revenue of between $134 million and $136 million, an increase of between 19% and 21% Testing volume of approximately 45,500, an increase of 16%. Total revenue of between $515 million and $517 million, an increase of approximately 16% Testing revenue of between...

#VCYT Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

www.stocktitan.net/news/VCYT/veracyte-annou...

Veracyte Announces Third Quarter 2025 Financial Results Veracyte, Inc., a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025.. Increased total revenue by 14% to $131.9 million and testing revenue by 17% to $127.8 million. Increased total volume by 18% to 45,888 tests and testing volume by 19% to 43,679 tests. Grew Decipher revenue by 26% to $82.2...

#VCYT Veracyte Announces Third Quarter 2025 Financial Results

www.stocktitan.net/news/VCYT/veracyte-annou...

72% Success Rate: Veracyte's Breakthrough Biomarker Revolutionizes Prostate Cancer Treatment Selection at ASTRO 2025 First prospective validation shows PAM50 biomarker predicts hormone therapy benefit in recurrent prostate cancer. 72% success in luminal B patients vs 54% placebo over 5-year study of 295 men.

#VCYT Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

www.stocktitan.net/news/VCYT/veracyte-annou...

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer Veracyte (NASDAQ:VCYT) announced groundbreaking results from the Phase 3 STAMPEDE trial, published in Cell, demonstrating that their Decipher Prostate Genomic Classifier can predict chemotherapy effectiveness in metastatic prostate cancer patients.The study of 1,523 patients revealed that those with higher Decipher scores showed improved survival benefit from docetaxel treatment (HR 0.64), while those with lower scores did not benefit significantly (HR 0.96). The trial followed patients for a median of 14 years.Veracyte launched the expanded Decipher test for metastatic prostate cancer in June 2025, addressing an urgent need as prostate cancer causes nearly 400,000 deaths globally and is the second-leading cause of cancer deaths among U.S. men, with 315,000 new diagnoses expected this year.

#VCYT Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

www.stocktitan.net/news/VCYT/veracyte-annou...

Breakthrough 97% Accurate: Veracyte's Simple Nasal Swab Could Transform Lung Cancer Detection Biotech firm completes enrollment in NIGHTINGALE trial across 90 US centers. Percepta Nasal Swab test shows 97% sensitivity for low-risk nodules, aims to reduce unnecessary procedures.

#VCYT Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

www.stocktitan.net/news/VCYT/veracyte-compl...

Veracyte Announces Second Quarter 2025 Financial Results Veracyte (NASDAQ:VCYT) reported strong Q2 2025 financial results with total revenue growing 14% year-over-year to $130.2 million. Testing revenue increased 14% to $122.3 million, driven by exceptional performance of Decipher tests, which achieved a 28% volume growth. The company recorded a GAAP net loss of $1.0 million, including $20.5 million in one-time impairment charges related to French subsidiary restructuring.Key highlights include Decipher revenue growth of 24% to $76.3 million and Afirma revenue increase of 5% to $43.4 million. The company generated $33.6 million in operating cash flow and ended the quarter with $320.7 million in cash and equivalents. Following strong performance, Veracyte raised its full-year 2025 testing revenue guidance to $477-483 million and adjusted EBITDA margin guidance to 23.5%.

#VCYT Veracyte Announces Second Quarter 2025 Financial Results

www.stocktitan.net/news/VCYT/veracyte-annou...

Veracyte Secures Major Index Upgrade: Latest Healthcare Addition to S&P SmallCap 600 Healthcare diagnostics firm Veracyte earns spot in prestigious S&P SmallCap 600 index. See how this institutional upgrade could impact trading volumes. Get details.

#VCYT #SPGI #TGI Veracyte Set to Join S&P SmallCap 600

www.stocktitan.net/news/VCYT/veracyte-set-t...

Veracyte Advances Thyroid Cancer Research: 3 New Molecular Studies Reveal Disease Drivers at ENDO 2025 Breakthrough genomic research using Afirma GRID database unveils new insights into thyroid cancer molecular drivers. Learn how this impacts future treatment. See findings.

#VCYT Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

www.stocktitan.net/news/VCYT/veracyte-annou...

Breakthrough Cancer Study: How Veracyte's Genomic Test Predicts 43% Better Survival in Prostate Cancer Patients New clinical data reveals genomic test predicts chemotherapy effectiveness in metastatic prostate cancer. Key survival metrics from 14-year study unveiled. See complete findings.

#VCYT Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

www.stocktitan.net/news/VCYT/veracyte-annou...

Veracyte Announces First Quarter 2025 Financial Results Veracyte (NASDAQ: VCYT) reported strong Q1 2025 financial results with total revenue reaching $114.5 million, up 18% year-over-year. The company achieved its eleventh consecutive quarter of 20%+ testing volume growth, primarily driven by Decipher and Afirma tests. Key highlights include: - Testing revenue increased 19% to $107.3 million - Total testing volume grew 22% to 40,655 tests - Decipher revenue surged 33% to $66.6 million - Net income reached $7.0 million (6.2% of revenue) - Adjusted EBITDA was $24.7 million (21.6% of revenue) The company maintained its 2025 testing revenue guidance of $470-480 million (12-15% growth) and raised adjusted EBITDA margin guidance to 22.5%. Additionally, Veracyte announced plans to discontinue funding its French subsidiary, with court proceedings expected to complete by end of 2025.

#VCYT Veracyte Announces First Quarter 2025 Financial Results

www.stocktitan.net/news/VCYT/veracyte-annou...

Breakthrough: Veracyte's Prostate Cancer Test Data Now Connected to 560,000+ Cases in National Cancer Database Major validation as Decipher genomic classifier connects with NCI's prestigious SEER database, unlocking insights from 560,000+ prostate cancer cases. See research impact.

#VCYT Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release

www.stocktitan.net/news/VCYT/veracyte-annou...

Revolutionary Blood Test Detects Cancer Return 3 Months Earlier Than Imaging New whole-genome sequencing platform outperforms current methods with 88% specificity, detecting bladder cancer recurrence 93 days before imaging. Full analysis inside.

#VCYT New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

www.stocktitan.net/news/VCYT/new-data-demon...

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25 Veracyte (VCYT) announced multiple abstract presentations at the 40th Annual European Association of Urology Congress (EAU25) in Madrid, Spain, showcasing the clinical performance and utility of its Decipher tests for prostate and bladder cancer. The company will also present independent performance data from a large, multicenter trial (TOMBOLA) supporting their minimal residual disease (MRD) testing platform for muscle-invasive bladder cancer.Dr. Philip Febbo, Veracyte's chief scientific officer and chief medical officer, highlighted how their whole-transcriptome approach enables partnerships with researchers to gain new insights into cancer biology. The company plans to launch an MRD test for muscle-invasive bladder cancer next year, utilizing their whole-genome approach.

#VCYT Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

www.stocktitan.net/news/VCYT/veracyte-annou...

Can Veracyte's 10th Straight Quarter of 20%+ Growth Signal a Diagnostic Testing Powerhouse? Healthcare diagnostics leader posts $118.6M revenue, driven by 24% testing growth. Achieves profitability with $24.1M net income and strong cash flow generation.

#VCYT Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/VCYT/veracyte-annou...

Revolutionary Cancer Test Results: Veracyte's Decipher Unlocks Personalized Treatment Success New clinical data validates Decipher tests' effectiveness in optimizing radiation therapy for prostate cancer and identifying less aggressive bladder cancers.

#VCYT New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

www.stocktitan.net/news/VCYT/new-data-at-as...

Veracyte's Decipher Tests Dominate ASCO GU 2025 with Groundbreaking Cancer Detection Results Leading cancer diagnostics firm showcases 17 studies validating Decipher tests' superior accuracy in prostate and bladder cancer treatment decisions at ASCO GU.

#VCYT Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

www.stocktitan.net/news/VCYT/veracyte-annou...

Clinical Study: Revolutionary Bladder Cancer Test Predicts Disease Progression with 33% Higher Accuracy New research validates Veracyte's Decipher Bladder test in predicting cancer progression, showing significant accuracy in identifying patients needing aggressive treatment across 8 medical centers.

#VCYT New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

www.stocktitan.net/news/VCYT/new-study-show...

Cancer Diagnostics Leader Veracyte Schedules Critical Year-End Financial Results Veracyte announces Q4 and 2024 financial results release scheduled for February 24, with management hosting conference call and webcast at 4:30 PM ET to discuss performance.

#VCYT Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

www.stocktitan.net/news/VCYT/veracyte-to-re...

Veracyte's Decipher Test Makes Breakthrough: Only Gene Expression Test in 2025 NCCN Prostate Cancer Guidelines | VCYT Stock News Veracyte's 22-gene Decipher test achieves landmark recognition in NCCN prostate cancer guidelines, backed by extensive Phase 3 trials validation. Learn how it's transforming treatment decisions.

#VCYT Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

#cancer #stocks #news

www.stocktitan.net/news/VCYT/veracyte-s-dec...